Condition

High Risk Myelodysplastic Syndrome clinical trials and research

• 10Clinical trials
• 1NIH research projects
• 3Countries

Newest High Risk Myelodysplastic Syndrome clinical trials

All recruiting trials (10)

• AMX-883 in AML and high-risk MDS: a first-in-class dosing study

  This early-stage study tests AMX-883 alone and with another drug to see if it is safe and shows early signs of benefit in people with AML or high-risk MDS.

  Recruiting at 3 sites Phase 1 Amphista Therapeutics Ltd · New York, New York and 2 other locations · NCT07723703

• Metronomic Decitabine-Cedazuridine and Venetoclax therapy for relapsed/refractory AML and high-risk blood cancers

  This phase 2 trial tests a metronomic decitabine-cedazuridine plus venetoclax regimen versus azacitidine plus venetoclax in adults with relapsed/refractory AML or high-risk MDS/MPN.

  Recruiting Phase 2 Virginia Commonwealth University · Richmond, Virginia · NCT07710534

• CBX-250 for relapsed or refractory myeloid leukemias.

  This will try CBX-250, a new injectable medicine, in people aged 12 and older with relapsed or refractory AML, high-risk MDS, CMML, or CML to see if it can control disease with tolerable side effects.

  Recruiting at 11 sites Phase 1 Crossbow Therapeutics, Inc. · Duarte, California and 10 other locations · NCT06994676

• Testing VIP943 for advanced blood cancers

  This study is testing a new drug called VIP943 to see if it can safely help people with advanced blood cancers like leukemia and myelodysplastic syndrome who have run out of other treatment options.

  Recruiting at 5 sites Phase 1 Vincerx Pharma, Inc. · Birmingham, Alabama and 4 other locations · NCT06034275

• Precision medicine approach for leukemia treatment

  This study is trying to find better ways to treat people with newly diagnosed leukemia by collecting data to create personalized treatment plans.

  Recruiting at 3 sites Assistance Publique - Hôpitaux de Paris · Bobigny and 2 other locations · NCT05326919

• Combining cladribine, idarubicin, cytarabine, and quizartinib for treating acute myeloid leukemia and high-risk myelodysplastic syndrome

  This study is testing a new combination of four drugs to see if it can help people with acute myeloid leukemia or high-risk myelodysplastic syndrome live longer and feel better.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT04047641

• Using edetate calcium disodium or succimer to treat acute myeloid leukemia or myelodysplastic syndrome during chemotherapy

  This study is testing whether two drugs, edetate calcium disodium and succimer, can safely help people with acute myeloid leukemia or myelodysplastic syndrome feel better during chemotherapy.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT03630991

• Using dexrazoxane to protect the heart during chemotherapy for blood cancers

  This study is testing if a drug called dexrazoxane can help protect the hearts of people with blood cancers from damage caused by chemotherapy.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT03589729

• Combining venetoclax with chemotherapy for treating acute myeloid leukemia

  This study is testing if combining a drug called venetoclax with chemotherapy can help people with newly diagnosed or tough-to-treat acute myeloid leukemia feel better and improve their chances of recovery.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT03214562

• Combination chemotherapy for newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

  This study is testing a mix of chemotherapy drugs to see if they can help people with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome achieve remission and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT00801489

NIH-funded research (1)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Understanding how immune evasion occurs in high-risk myelodysplastic syndrome

  This study is looking at how a protein called VISTA helps high-risk myelodysplastic syndrome (HR-MDS) avoid being attacked by the immune system, with the goal of finding new ways to improve treatments for patients like you.

  NIH research Vanderbilt University · Nashville, UNITED STATES · NIH-11069224

Related topics

Quick answers

How many High Risk Myelodysplastic Syndrome clinical trials are recruiting right now?

10, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 3 countries. The most sites are in United States (9 trials), France (1 trial), United Kingdom (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 4, Phase 2: 3, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →